ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
0,00%
Bitcoin
67.153,05
0,32%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Amryt Pharma PLC (AMYT)

  7. Amryt Pharma PLC (AMYT) News

AMYT

Amryt Pharma (AMYT)

Amryt Pharma PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AMYT
DatumZeitQuelleÜberschriftSymbolFirma
18/04/202323h02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AMYTAmryt Pharma PLC
18/04/202323h01Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AMYTAmryt Pharma PLC
18/04/202322h16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AMYTAmryt Pharma PLC
12/04/202323h29Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
12/04/202314h21Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AMYTAmryt Pharma PLC
12/04/202313h58PR Newswire (US)Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma PlcNASDAQ:AMYTAmryt Pharma PLC
12/04/202313h00GlobeNewswire Inc.Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma PlcNASDAQ:AMYTAmryt Pharma PLC
11/04/202315h00GlobeNewswire Inc.2022 for Chiesi: The Group’s international growth continuesNASDAQ:AMYTAmryt Pharma PLC
03/04/202315h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
23/03/202314h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
16/02/202313h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
13/02/202316h25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AMYTAmryt Pharma PLC
10/02/202322h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AMYTAmryt Pharma PLC
10/02/202315h49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AMYTAmryt Pharma PLC
09/01/202322h06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
07/11/202204h35TipRanksSVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)NASDAQ:AMYTAmryt Pharma PLC
04/11/202219h55TipRanksAmryt Pharma (AMYT) Receives a Buy from Maxim GroupNASDAQ:AMYTAmryt Pharma PLC
04/11/202211h25TipRanksAmryt Pharma (AMYT) Receives a Buy from H.C. WainwrightNASDAQ:AMYTAmryt Pharma PLC
03/11/202212h45Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
19/09/202212h25TipRanksH.C. Wainwright Sticks to Its Buy Rating for Amryt Pharma (AMYT)NASDAQ:AMYTAmryt Pharma PLC
08/08/202214h27TipRanksH.C. Wainwright Keeps Their Buy Rating on Amryt Pharma (AMYT)NASDAQ:AMYTAmryt Pharma PLC
05/08/202219h25TipRanksMaxim Group Reiterates a Buy Rating on Amryt Pharma (AMYT)NASDAQ:AMYTAmryt Pharma PLC
14/07/202213h49Dow Jones NewsAmryt Gets FDA Orphan Designation for Mycapssa in Carcinoid SyndromeNASDAQ:AMYTAmryt Pharma PLC
26/06/202209h39TipRanksSVB Securities Keeps a Buy Rating on Amryt Pharma (AMYT)NASDAQ:AMYTAmryt Pharma PLC
24/06/202213h54Dow Jones NewsAmryt to Pursue Formal FDA Resolution for Oleogel-S10NASDAQ:AMYTAmryt Pharma PLC
24/06/202213h19Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
23/06/202213h26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AMYTAmryt Pharma PLC
23/05/202212h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AMYTAmryt Pharma PLC
20/05/202223h07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:AMYTAmryt Pharma PLC
20/05/202222h59Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:AMYTAmryt Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:AMYT

Kürzlich von Ihnen besucht

USOTC
LSNVY
Lai Sun Development (PK)
TSXV
TCA.PR.A
Timia Capital
LSE
0RO3
Concord Fund-7 South-eas...
AMEX
SPDW
SPDR Portfolio Developed...
NYSE
AI
C3 AI
GATE
NIIETH
Nahmii
USOTC
GGBBF
Lxrandco (CE)
ASX
NDXKOB
USOTC
MKULQ
Molekule (CE)
USOTC
VILGF
Yourgene Health (PK)
USOTC
KAJMY
Kajima (PK)
CRTO
LSKUSDT
Lisk
GATE
ZONEUSDT
ZONE
BITMOT
881793
Eu Sure Bond Tf 0% Gn28 ...
USOTC
DNTUF
Dentsu (PK)
USOTC
MRVCF
Metrovacesa (PK)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten